The Impact of Low Sodium Salt Substitute Use on Serum Potassium Levels Among Patients With Hypertension
Sponsor: Johns Hopkins University • ClinicalTrials.gov ID: NCT07460882
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
The goal of this pre-post study is to assess the risk of hyperkalemia in adults with hypertension on medication in Bangladesh. The main questions it aims to answer are: Is the risk of hyperkalemia after the initiation of Low Sodium Salt Substitute (LSSS) in people on antihypertensive medication (especially RASi) large enough to be concerned about its broad use in this population? Does initiation of LSSS correct hypokalemia in people on antihypertensive medication (especially RASi) with low serum potassium levels? Participants will be asked to reduce overall salt intake and to use LSSS on every occasion where regular salt would normally be used, including as cooking salt.
Interventions
-
Low-sodium salt substitute
(Dietary supplement)
The low sodium salt substitute contains 25% potassium chloride (KCl range; 20%-35%)
Eligibility criteria
Conditions
Locations
- The National Heart Foundation of Bangladesh — Dhaka, Bangladesh
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record